Since preclinical data suggested that TGF-β and VEGF signaling interactions could synergistically promote angiogenesis and immune evasion, their combined inhibition is a potential therapeutic strategy for HCC (Harding et al., 2021). The gene discussed is TGFB1; the disease is hepatocellular carcinoma.